Sandrine Boyault

Sandrine Boyault

Auto-generated profile, based on publicly available information

Sandrine Boyault

Department of Translationnal Research and Innovation, Centre de Recherche en Cancérologie de Lyon, INSERM U1052, CNRS UMR 5286, Centre Léon Bérard, UCBL1 , Lyon

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
NAN. Alcala
N. Alcala
NLN. Leblay
N. Leblay
AGA. A. G. Gabriel
A. A. G. Gabriel
LML. Mangiante
L. Mangiante
DHDavid Hervás
David Hervás
LFL. Fernandez-Cuesta
L. Fernandez-Cuesta
The worldwide incidence of pulmonary carcinoids is increasing, but little is known about their molecular characteristics. Through machine learning and multi-omics factor analysis, we compare and contrast the genomic profiles of 116 pulmonary carcinoids (including 35 atypical), 75 large-cell neuroendocrine carcinomas (LCNEC), and 66 small-cell lung cancers. Here we report that the integrative analyses on 257 lung neuroendocrine neoplasms stratify atypical carcinoids into two prognostic groups with a 10-year overall survival of 88% and 27%, respectively. We identify therapeutically relevant molecular groups of pulmonary carcinoids, suggesting DLL3 and the immune system as candidate therapeutic targets; we confirm the value ofOTPexpression levels for the prognosis and diagnosis of these diseases, and we unveil the group of supra-carcinoids. This group comprises samples with carcinoid-like morphology yet the molecular and clinical features of the deadly LCNEC, further supporting the previously proposed molecular link between the low- and high-grade lung neuroendocrine neoplasms.

7 September 2022 in Nature
Verified
Journal Article
Closed access
PDF file
FAFabrice Andre
Fabrice Andre
TFThomas Filleron
Thomas Filleron
MKMaud Kamal
Maud Kamal
FMFernanda Mosele
Fernanda Mosele
MAMonica Arnedos
Monica Arnedos
IBIvan Bieche
Ivan Bieche

16 March 2023 in Nature Genetics
Verified
Journal Article
Open access
PDF file
LMLise Mangiante
Lise Mangiante
NANicolas Alcala
Nicolas Alcala
ASAlexandra Sexton-Oates
Alexandra Sexton-Oates
AGAlex Di Genova
Alex Di Genova
AGAbel Gonzalez-Perez
Abel Gonzalez-Perez
LFLynnette Fernandez-Cuesta
Lynnette Fernandez-Cuesta
Malignant pleural mesothelioma (MPM) is an aggressive cancer with rising incidence and challenging clinical management. Through a large series of whole-genome sequencing data, integrated with transcriptomic and epigenomic data using multiomics factor analysis, we demonstrate that the current World Health Organization classification only accounts for up to 10% of interpatient molecular differences. Instead, the MESOMICS project paves the way for a morphomolecular classification of MPM based on four dimensions: ploidy, tumor cell morphology, adaptive immune response and CpG island methylator profile. We show that these four dimensions are complementary, capture major interpatient molecular differences and are delimited by extreme phenotypes that—in the case of the interdependent tumor cell morphology and adapted immune response—reflect tumor specialization. These findings unearth the interplay between MPM functional biology and its genomic history, and provide insights into the variations observed in the clinical behavior of patients with MPM.

22 April 2011 in Breast Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
SBSandrine Boyault
Sandrine Boyault
YDYouenn Drouet
Youenn Drouet
CNClaudine Navarro
Claudine Navarro
TBThomas BACHELOT
Thomas BACHELOT
CLChristine Lasset
Christine Lasset
QWQing Wang
Qing Wang
Understanding how cancer genes are mutated in individual tumors is an important issue with potential clinical and therapeutic impact. This is especially relevant with recently developed targeted therapies since mutated genes can be targets and/or predictors. However, to date, gene mutation profiling in individual tumors is still underexplored. Breast cancer is composed of various subtypes. We presumed that this heterogeneity reflected the involvement of different molecular mechanisms including gene mutations that affect defined signaling pathways. Unlike the majority of published mutational studies, this study was aimed to draw a mutation profile in individual tumors by screening a panel of cancer genes in the same tumor. Thus, five genes frequently mutated in breast cancers: TP53, PIK3CA, PTEN, CDH1, and AKT1 were screened in each of 120 human primary breast tumors. Mutations in at least one of these genes were found in 62.5% of the tumors, of which the majority carried a single-gene mutation. Interestingly, a substantial proportion of tumors carried mutations either in TP53 or in genes of the PI3K pathway (PIK3CA or PTEN or AKT1). These two distinct mutation patterns were significantly associated to hormone receptor expression but independent of HER2 status.

Verified
Journal Article
Open access
PDF file
JEJOBARD Elodie
JOBARD Elodie
OTOlivier Trédan
Olivier Trédan
DPDéborah Postoly
Déborah Postoly
FAFabrice André
Fabrice André
AMAnne-Laure Martin
Anne-Laure Martin
SBSandrine Boyault
Sandrine Boyault
The recent thriving development of biobanks and associated high-throughput phenotyping studies requires the elaboration of large-scale approaches for monitoring biological sample quality and compliance with standard protocols. We present a metabolomic investigation of human blood samples that delineates pitfalls and guidelines for the collection, storage and handling procedures for serum and plasma. A series of eight pre-processing technical parameters is systematically investigated along variable ranges commonly encountered across clinical studies. While metabolic fingerprints, as assessed by nuclear magnetic resonance, are not significantly affected by altered centrifugation parameters or delays between sample pre-processing (blood centrifugation) and storage, our metabolomic investigation highlights that both the delay and storage temperature between blood draw and centrifugation are the primary parameters impacting serum and plasma metabolic profiles. Storing the blood drawn at 4 °C is shown to be a reliable routine to confine variability associated with idle time prior to sample pre-processing. Based on their fine sensitivity to pre-analytical parameters and protocol variations, metabolic fingerprints could be exploited as valuable ways to determine compliance with standard procedures and quality assessment of blood samples within large multi-omic clinical and translational cohort studies.

7 April 2025 in Nature Medicine
Verified
Journal Article
Open access
PDF file
OTOlivier Trédan
Olivier Trédan
DPDamien Pouessel
Damien Pouessel
NPNicolas Penel
Nicolas Penel
SCSylvie Chabaud
Sylvie Chabaud
CGCarlos Gomez-Roca
Carlos Gomez-Roca
Jaen-Yves BlayJaen-Yves Blay
Jaen-Yves Blay
Large genomic programs have contributed to improving drug development in cancer. To assess the potential benefit of using larger gene panels to guide molecular-based treatments, we conducted a multicenter randomized trial in patients with advanced and/or metastatic solid cancer. Molecular alterations were determined using either a panel of 324 cancer-related genes (Foundation OneCDX (F1CDX)) or a limited panel of 87 single-nucleotide/indel genes and genome-wide copy number variations (CTL) and reviewed by a molecular tumor board to identify molecular-based recommended therapies (MBRTs). Using paired data from both panels for each patient, the primary endpoint was the proportion of patients with an MBRT identified. Main secondary endpoints included the number of patients with at least one actionable alteration leading to MBRT identification, the number of patients with and without MBRTs initiated, progression-free survival, best overall response, duration of response and safety. Among the 741 patients screened, 45.7% had quality-checked tumor samples. MBRTs were identified with F1CDX in 175 (51.6%) patients and with CTL in 125 (36.9%) patients, translating to a significant increase of 14.8 percentage points (P < 0.001) with the more comprehensive gene panel versus the more limited panel, meeting the primary endpoint. However, no differences in clinical outcomes were observed in these patients with advanced and/or metastatic cancer in need of treatment beyond standard genomic alterations. These findings illustrate the potential for larger gene panels to increase the number of molecularly matched therapies. Larger studies are needed to assess the clinical benefit of expanded MBRTs. ClinicalTrials.gov registration: NCT03163732.